[go: up one dir, main page]

HUP9902952A1 - Ionos komplex formájú, vízoldható gyógyászati készítmény és alkalmazása - Google Patents

Ionos komplex formájú, vízoldható gyógyászati készítmény és alkalmazása

Info

Publication number
HUP9902952A1
HUP9902952A1 HU9902952A HUP9902952A HUP9902952A1 HU P9902952 A1 HUP9902952 A1 HU P9902952A1 HU 9902952 A HU9902952 A HU 9902952A HU P9902952 A HUP9902952 A HU P9902952A HU P9902952 A1 HUP9902952 A1 HU P9902952A1
Authority
HU
Hungary
Prior art keywords
copositions
water
ionic complex
soluble pharmaceutical
subject
Prior art date
Application number
HU9902952A
Other languages
English (en)
Inventor
Apollon Papadimitriou
Original Assignee
F. Hoffmann La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann La Roche Ag. filed Critical F. Hoffmann La Roche Ag.
Publication of HU9902952D0 publication Critical patent/HU9902952D0/hu
Publication of HUP9902952A1 publication Critical patent/HUP9902952A1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgyát biőlógiailag aktív pőlipeptidet tartalmazókészítmények képezik, mely készítmények hatóanyagánakhatásmechanizműsa a sejtmembránőn elhelyezkedő extracellűlárisreceptőrral történő kölcsönhatásőn alapűl, és a pőlipeptid akészítményben amfifil vegyülettel képzett iőnős kőmplex főrmájában vanjelen. A találmány tárgyát képezi tővábbá a találmány szerintimegőldás alkalmazása biőlógiailag aktív pőlipeptidek hatékőnyságánakfőkőzására és/vagy a hatóanyag késleltetett felszabadűlásánakelősegítésére. ŕ
HU9902952A 1998-09-01 1999-09-01 Ionos komplex formájú, vízoldható gyógyászati készítmény és alkalmazása HUP9902952A1 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98116494 1998-09-01

Publications (2)

Publication Number Publication Date
HU9902952D0 HU9902952D0 (en) 1999-10-28
HUP9902952A1 true HUP9902952A1 (hu) 2000-06-28

Family

ID=8232558

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902952A HUP9902952A1 (hu) 1998-09-01 1999-09-01 Ionos komplex formájú, vízoldható gyógyászati készítmény és alkalmazása

Country Status (30)

Country Link
US (3) US6867182B2 (hu)
EP (1) EP1002547B1 (hu)
JP (1) JP3664373B2 (hu)
KR (1) KR100403075B1 (hu)
CN (1) CN1325118C (hu)
AR (1) AR023044A1 (hu)
AT (1) ATE318616T1 (hu)
AU (1) AU755930B2 (hu)
BR (1) BR9903984B1 (hu)
CA (1) CA2281049C (hu)
CO (1) CO5271726A1 (hu)
DE (1) DE69930033T2 (hu)
ES (1) ES2258830T3 (hu)
GC (1) GC0000107A (hu)
HR (1) HRP990272B1 (hu)
HU (1) HUP9902952A1 (hu)
ID (1) ID22964A (hu)
IL (1) IL131626A0 (hu)
MA (1) MA26682A1 (hu)
MY (1) MY127935A (hu)
NO (1) NO994214L (hu)
NZ (1) NZ337527A (hu)
PE (1) PE20001027A1 (hu)
PL (1) PL194218B1 (hu)
RU (1) RU2180855C2 (hu)
SG (1) SG85670A1 (hu)
TR (1) TR199902103A2 (hu)
TW (1) TW570805B (hu)
YU (1) YU42399A (hu)
ZA (1) ZA995601B (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
CN1802171B (zh) * 2003-06-10 2010-10-13 株式会社Lg生命科学 不包含血清白蛋白的人红细胞生成素的稳定水溶液
UA71839C2 (uk) * 2003-12-30 2007-06-25 Товариство З Обмеженою Відповідальністю "Фарм-Стом" Фармацевтична композиція на основі артикаїну та епінефрину
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
SI2422789T1 (en) * 2004-05-19 2018-07-31 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Injectable coposition comprising sodium deoxycholate
US20090214625A1 (en) * 2005-07-15 2009-08-27 Mizuo Nakayama Drug delivery patch
JP2007037868A (ja) * 2005-08-05 2007-02-15 Transcutaneous Technologies Inc 経皮投与装置及びその制御方法
US20070042041A1 (en) * 2005-08-17 2007-02-22 Board Of Trustees Of The University Of Arkansas Drug-surfactant complexes for sustained release
EP1925335A1 (en) * 2005-09-16 2008-05-28 Tti Ellebeau, Inc. Catheter type iontophoresis apparatus
CA2622777A1 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Iontophoresis device to deliver multiple active agents to biological interfaces
WO2007079116A1 (en) * 2005-12-28 2007-07-12 Tti Ellebeau, Inc. Electroosmotic pump apparatus and method to deliver active agents to biological interfaces
WO2007079193A2 (en) * 2005-12-30 2007-07-12 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
US20080004564A1 (en) * 2006-03-30 2008-01-03 Transcutaneous Technologies Inc. Controlled release membrane and methods of use
RU2009103771A (ru) * 2006-07-05 2010-08-10 ТиТиАй ЭЛЛЕБО, ИНК. (JP) Устройство для доставки, включающее самособирающиеся ветвящиеся полимеры, и способ его применения
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
JP5864834B2 (ja) 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス プロテアーゼ耐性のインスリンアナログ
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
FR2908414B1 (fr) 2006-11-13 2012-01-20 Centre Nat Rech Scient Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
JPWO2008087803A1 (ja) * 2007-01-16 2010-05-06 国立大学法人北海道大学 抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
ES2563038T3 (es) 2007-04-30 2016-03-10 Novo Nordisk A/S Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
EP2164458A1 (en) * 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
JP2010187707A (ja) * 2007-06-12 2010-09-02 Hokkaido Univ インスリンを封入したイオントフォレーシス用リポソーム製剤
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
KR20110086799A (ko) * 2008-09-10 2011-08-01 트란스큐 리미티드 Ｈｐｃ-기재 점성질 액체를 다공성 기판에 주입하기 위한 기구 및 방법, 예를 들어 연속적 웹-기반 프로세스
WO2012134540A2 (en) * 2010-10-22 2012-10-04 Vanderbilt University Injectable synthetic pur composite
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
AU2010334428B2 (en) * 2009-12-22 2015-05-21 Celldex Therapeutics, Inc. Vaccine compositions
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
MX344635B (es) 2012-03-23 2017-01-04 Amicrobe Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con el tejido.
BR112014025132A2 (pt) 2012-04-11 2017-07-11 Novo Nordisk As formulações de insulina
ES2676065T3 (es) 2013-10-07 2018-07-16 Novo Nordisk A/S Nuevo derivado de un análogo de la insulina
KR101945498B1 (ko) * 2015-11-04 2019-02-08 포항공과대학교 산학협력단 양이온성 분자 수송체 및 단백질을 포함하는 피부 투과용 조성물
HUE060149T2 (hu) 2016-12-16 2023-02-28 Novo Nordisk As Inzulint tartalmazó gyógyászati készítmények
US11285189B2 (en) 2017-04-06 2022-03-29 Amicrobe, Inc. Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
EP3946457A1 (en) * 2019-04-01 2022-02-09 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
JPS61500790A (ja) 1984-03-28 1986-04-24 シタス　コ−ポレイシヨン 微生物的に製造されたインターロイキン―２を含有する組成物
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
LU85971A1 (fr) * 1985-06-25 1987-01-13 Oreal Nouveaux composes lipidiques amphiphiles, leur procede de preparation et leurs applications,notamnent en cosmetique et en dermopharmacie
JPS62207226A (ja) 1986-03-07 1987-09-11 Sumitomo Pharmaceut Co Ltd 経鼻投与用製剤
FR2615194B1 (fr) * 1987-05-11 1991-06-14 Rhone Poulenc Chimie Particules de polymere comportant, implantees a leur surface des molecules amphiphiles portant des groupes ionogenes ou reactifs, leur procede de preparation et leur application en biologie
WO1989010758A1 (en) * 1988-05-02 1989-11-16 Zynaxis Technologies, Inc. Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
FR2694559B1 (fr) * 1992-08-06 1994-10-28 Atta Nouveaux dérivés amphiphiles d'aminoacides ou de peptides, leur procédé de préparation et leur utilisation dans des préparations à usage biomédical.
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
JP3290745B2 (ja) 1993-03-31 2002-06-10 藤平 正道 単分子膜のパターン形成方法
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5789543A (en) * 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
US20030186357A1 (en) * 1993-12-30 2003-10-02 Philip W. Ingham Vertebrate embryonic pattern-inducing proteins, and uses related thereto
WO1995018856A1 (en) * 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
FR2714621B1 (fr) 1994-01-06 1996-02-23 Centre Nat Rech Scient Procédé de préparation de liposomes sans utilisation de solvant organique.
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5853741A (en) * 1996-06-28 1998-12-29 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Vitamin C delivery system
CA2267106A1 (en) * 1996-10-07 1998-07-16 The Johns Hopkins University School Of Medicine Novel hedgehog-derived polypeptides
RU2179981C2 (ru) 1996-10-15 2002-02-27 Сейкагаку Корпорейшн Соли переходного металла с полипептидом и способ повышения активности полипептида против вич
WO1998020298A1 (en) * 1996-11-08 1998-05-14 Northern Magnetics, Inc. Sensing and controlling the location of elements of a linear motor
US5759811A (en) * 1996-11-13 1998-06-02 The Regents Of The University Of California Mutant human hedgehog gene
JPH10194987A (ja) * 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
JPH114695A (ja) * 1997-04-25 1999-01-12 Hayashibara Biochem Lab Inc ヘッジホッグ蛋白質
US6639051B2 (en) * 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
EP0917879B1 (de) 1997-11-22 2002-07-17 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Stabilisierung von Proteinen
EP0919618A1 (de) 1997-11-28 1999-06-02 Boehringer Mannheim Gmbh Aktive Hedgehog-Protein-Mutante, Verfahren zur Herstellung und Verwendung
CA2309806A1 (en) 1997-12-03 1999-06-10 Biogen, Inc. Hydrophobically-modified protein compositions and methods
JP3648051B2 (ja) * 1998-02-02 2005-05-18 富士通株式会社 関連情報検索装置及びプログラム記録媒体
EP0947201B1 (en) * 1998-02-04 2006-06-28 Curis, Inc. Pharmaceutical composition of hedgehog proteins and use thereof
CA2260423C (en) 1998-02-04 2006-06-20 Kurt Lang Pharmaceutical composition of hedgehog proteins and use thereof
EP1557427A3 (en) * 1998-04-30 2005-10-19 Curis, Inc. Hedgehog protein conjugate
US20050021440A1 (en) * 2003-04-04 2005-01-27 Scott Dresden Integrated dynamic pricing and procurement support for e-commerce advertising channels
WO2005029362A1 (en) * 2003-09-22 2005-03-31 Eurekster, Inc. Enhanced search engine
US20050114319A1 (en) * 2003-11-21 2005-05-26 Microsoft Corporation System and method for checking a content site for efficacy
US10515374B2 (en) * 2005-03-10 2019-12-24 Adobe Inc. Keyword generation method and apparatus

Also Published As

Publication number Publication date
US20020028766A1 (en) 2002-03-07
AU4486699A (en) 2000-03-16
RU2180855C2 (ru) 2002-03-27
TR199902103A2 (xx) 2000-04-21
IL131626A0 (en) 2001-01-28
AU755930B2 (en) 2003-01-02
MY127935A (en) 2007-01-31
US20050123610A1 (en) 2005-06-09
ZA995601B (en) 2000-09-27
NO994214D0 (no) 1999-08-31
US6867182B2 (en) 2005-03-15
NZ337527A (en) 2000-12-22
TW570805B (en) 2004-01-11
CO5271726A1 (es) 2003-04-30
SG85670A1 (en) 2002-01-15
EP1002547A1 (en) 2000-05-24
PL194218B1 (pl) 2007-05-31
AR023044A1 (es) 2002-09-04
CA2281049C (en) 2010-11-02
PL335203A1 (en) 2000-03-13
YU42399A (sh) 2001-05-28
DE69930033T2 (de) 2006-10-12
US8519098B2 (en) 2013-08-27
BR9903984B1 (pt) 2011-04-19
DE69930033D1 (de) 2006-04-27
HU9902952D0 (en) 1999-10-28
GC0000107A (en) 2005-06-29
ATE318616T1 (de) 2006-03-15
HRP990272A2 (en) 2000-06-30
ID22964A (id) 1999-12-23
CN1325118C (zh) 2007-07-11
NO994214L (no) 2000-03-02
US20080064854A1 (en) 2008-03-13
HRP990272B1 (en) 2006-11-30
BR9903984A (pt) 2001-03-13
KR100403075B1 (ko) 2003-10-30
JP3664373B2 (ja) 2005-06-22
JP2000086532A (ja) 2000-03-28
PE20001027A1 (es) 2000-10-13
EP1002547B1 (en) 2006-03-01
CN1250669A (zh) 2000-04-19
CA2281049A1 (en) 2000-03-01
KR20000022777A (ko) 2000-04-25
ES2258830T3 (es) 2006-09-01
MA26682A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
HUP9902952A1 (hu) Ionos komplex formájú, vízoldható gyógyászati készítmény és alkalmazása
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
BR9913857A (pt) Formulações de proteìna
HRP20010463B1 (hr) Smjesa s kontroliranim otpuštanjem koja sadrži galantamin
FI861923A7 (fi) Suulakepuristettavien mikropartikkeleidenvalmistuksessa käytettäviä koostumuksia, jotka aiheuttavat biologisestaktiivisen aineen pitkittyneen vapautumisen, ja näin saadut mikropartikkelit.
TR199802423T2 (xx) Konsantre antikor terkibi.
NO965012D0 (no) Farmasöytisk preparat som omfatter glukagon
ATE206308T1 (de) Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
NO20064159L (no) Nye, biologisk aktive polypeptider, deres fremstilling og farmasoytiske preparater inneholdende polypeptidene
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
TR200100361T2 (tr) Yeni oral formülasyon
BR0013012A (pt) Composição contendo substância ativa, sua produção e seu uso
HUP9700826A1 (hu) Peptikus fekély elleni gyógyászati készítmények
PT975334E (pt) Microparticulas biodegradaveis para a libertacao sustentada de farmacos terapeuticos
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
ES2167939T3 (es) Nuevas poliaminas, su preparacion y usos.
EP0800828A4 (en) TRANSMUCOSAL PREPARATION
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
TR200103090T2 (tr) Integrın reseptör antagonistleri
BR9714279A (pt) Preparação aquosa, e, uso da mesma.
WO2000066173A3 (en) Targeting of infectious agents bearing host cell proteins
BG103739A (en) Aqueous pharmaceutical composition containing hard soluble active substance in water
FI843609A7 (fi) Nestemäiset, ionisia aineosia sisältävät farmaseuttiset valmisteet, jotka pidentävät lääkeaineen vapautumista.
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees